69 results
Page 3 of 4
8-K
EX-99.1
mmqr2544
21 Jun 21
Regulation FD Disclosure
8:15am
8-K
8rxhp5zt3s
21 Jun 21
Regulation FD Disclosure
8:15am
S-3ASR
kify92
18 May 21
Automatic shelf registration
6:01am
8-K
EX-99.1
3hy o9h0w
13 May 21
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
7:18am
8-K
EX-99.1
uimacr 2e
22 Mar 21
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
4:05pm
8-K
8dfxuf
22 Mar 21
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
4:05pm
8-K
EX-99.2
764z3
22 Mar 21
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
4:05pm
8-K
EX-99.1
fhqm pw20uma2kbbfs
16 Mar 21
Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
8:10am
8-K
EX-99.1
rldh0lspg9i7 8mvd
11 Jan 21
A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. JP Morgan Presentation January 2021
7:01am
8-K
EX-99.1
07rpne aeghu
16 Nov 20
A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. Corporate Presentation November 2020
6:30am
8-K
EX-99.1
a76gn djt
12 Nov 20
Akero Therapeutics Reports THIRD Quarter 2020 Financial Results
4:20pm
8-K
EX-99.1
bzkrvzl
15 Oct 20
A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. Corporate Presentation October 2020
8:30am
8-K
EX-99.1
jeijki
12 Aug 20
Akero Therapeutics Reports SECOND Quarter 2020 Financial Results
4:25pm
424B4
z8w7cy1 gc
8 Jul 20
Prospectus supplement with pricing info
8:30pm
S-3
crpee76b3 8sn
1 Jul 20
Shelf registration
4:08pm